Contract research organization Molecular Imaging has signed a licensing agreement with Dana-Farber Cancer Institute to access luciferase-enabled cancer cell lines developed at the institute.
The agreement is designed to expand the company's ability to apply its bioluminescent imaging technology to cancer disease models, including leukemia, multiple myeloma, triple-negative breast cancer, glioma, and melanoma, the firm said.
